ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The Company's segments include Domestic and European. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations. The European region contains its subsidiary located in Italy. Its tests are based on a range of technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology and cell separation, as well as high performance liquid chromatography (HPLC) separations, all of which are clinical testing methodologies used across the world. It also designs and manufactures laboratory instruments that perform the tests.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSEMKT:ERB
- CUSIP: N/A
- Web: erbadiagnostics.com
- 50 Day Moving Avg: $0.50
- 200 Day Moving Avg: $0.51
- 52 Week Range: $0.47 - $1.19
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.50
- P/E Growth: 0.00
- Net Margins: -9.30%
- Return on Equity: -13.27%
- Return on Assets: -8.83%
Frequently Asked Questions for ERBA Diagnostics (NYSEMKT:ERB)
What is ERBA Diagnostics' stock symbol?
ERBA Diagnostics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ERB."
How were ERBA Diagnostics' earnings last quarter?
ERBA Diagnostics Inc (NYSEMKT:ERB) released its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The firm had revenue of $5.90 million for the quarter, compared to the consensus estimate of $5.16 million. ERBA Diagnostics had a negative net margin of 9.30% and a negative return on equity of 13.27%. View ERBA Diagnostics' Earnings History.
Who are some of ERBA Diagnostics' key competitors?
Some companies that are related to ERBA Diagnostics include Johnson & Johnson (JNJ), Roche Holding (RHHBY), Novartis AG (NVS), Pfizer (PFE), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), AbbVie (ABBV), Medtronic PLC (MDT), Bayer AG (BAYRY), Celgene Corporation (CELG), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Gilead Sciences (GILD), Eli Lilly and Company (LLY), Bristol-Myers Squibb Company (BMY) and Abbott Laboratories (ABT).
Who are ERBA Diagnostics' key executives?
ERBA Diagnostics' management team includes the folowing people:
- Suresh H. Vazirani, Executive Chairman of the Board
- Hayden Jeffreys, Interim Chief Executive Officer, Director
- Chandra Krishnan, Senior Vice President - Global Sales, Marketing and Business Development
- Nikhil Vazirani, Director
- Gerald E. Gallwas, Independent Director
- David M. Templeton, Independent Director
How do I buy ERBA Diagnostics stock?
Shares of ERBA Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ERBA Diagnostics' stock price today?
MarketBeat Community Rating for ERBA Diagnostics (NYSEMKT ERB)MarketBeat's community ratings are surveys of what our community members think about ERBA Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ERBA Diagnostics stock can currently be purchased for approximately $0.50.
Consensus Ratings for ERBA Diagnostics (NYSEMKT:ERB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for ERBA Diagnostics (NYSEMKT:ERB)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for ERBA Diagnostics (NYSEMKT:ERB)Earnings History by Quarter for ERBA Diagnostics (NYSEMKT ERB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/5/2015||Q215||($0.02)||($0.01)||$5.16 million||$5.90 million||View||N/A|
|5/18/2015||Q115||$0.01||($0.01)||$8.10 million||$12.60 million||View||N/A|
|8/12/2014||Q214||$0.01||$6.74 million||$7.54 million||View||N/A|
|11/14/2012||Q312||($0.01)||$4.06 million||$3.80 million||View||N/A|
Earnings Estimates for ERBA Diagnostics (NYSEMKT:ERB)
Current Year EPS Consensus Estimate: $-0.06 EPS
Next Year EPS Consensus Estimate: $-0.04 EPS
Dividend History for ERBA Diagnostics (NYSEMKT:ERB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ERBA Diagnostics (NYSEMKT:ERB)Insider Trades by Quarter for ERBA Diagnostics (NYSEMKT:ERB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/15/2014||Gopalkrishnan Mohan||CEO||Buy||5,000||$2.89||$14,450.00|| |
Headline Trends for ERBA Diagnostics (NYSEMKT:ERB)
Latest Headlines for ERBA Diagnostics (NYSEMKT:ERB)
|Worldwide $60.5 Billion Market for In Vitro Diagnostic (IVD) Tests, 2021 - Research and Markets|
www.bizjournals.com - April 7 at 9:59 PM
|Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against ERBA Diagnostics, Inc. and Lead Plaintiff Deadline: February 1, 2016|
finance.yahoo.com - April 7 at 9:38 AM
|DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against ERBA Diagnostics, Inc. and Lead Plaintiff Deadline: February 1, 2016|
finance.yahoo.com - April 7 at 9:38 AM
|Blood Gas and Electrolyte Analyzers Market: EME Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016-2024|
www.bizjournals.com - February 17 at 5:35 PM
|ERBA Diagnostics (ERBA) Names New CEO|
www.streetinsider.com - November 30 at 5:03 PM
|ERBA Diagnostics (ERB) Will Begin Trading OTC Under 'ERBA'|
www.streetinsider.com - October 2 at 9:23 AM
|ERBA DIAGNOSTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - September 29 at 4:50 PM
|ReportLinker Review : Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021|
www.prnewswire.com - September 27 at 9:27 AM
|Antinuclear Antibody Testing Market Worth USD 1,476.1 Million USD by 2021|
finance.yahoo.com - September 21 at 5:22 PM
|ERBA DIAGNOSTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Ex|
biz.yahoo.com - September 7 at 5:00 PM
|BRIEF-Erba Diagnostics announces NYSE notice of noncompliance|
www.reuters.com - August 27 at 9:30 AM
|The Worldwide Market for In Vitro Diagnostic Tests, 10th Edition|
www.prnewswire.com - August 26 at 6:40 AM
|BRIEF-Erba Diagnostics files for non-timely 10-Q - Sec Filing|
www.reuters.com - August 18 at 10:12 PM
|ERBA DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princip|
biz.yahoo.com - May 31 at 4:32 PM
|ERBA Diagnostics, Inc. Announces Extension of CEO’S Contract Term and Appointment of Hayden Jeffreys to Board of Directors|
finance.yahoo.com - May 31 at 4:15 PM
|ERBA Diagnostics (ERB) Receives Notice of Noncompliance With NYSE Continued Listing Standards|
www.streetinsider.com - May 21 at 2:47 PM
|Blood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023|
www.prnewswire.com - May 13 at 9:33 AM